Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 108

1.

Does the pattern of bicuspid aortic valve leaflet fusion determine the success of the Ross procedure?

Ruzmetov M, Fortuna RS, Shah JJ, Welke KF, Plunkett MD.

J Card Surg. 2019 Oct 26. doi: 10.1111/jocs.14294. [Epub ahead of print]

PMID:
31654591
2.

A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ.

Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. No abstract available.

3.

A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Lee HC, Shah JJ, Feng L, Morphey A, Johnson RJ, Wesson ET, Wang ML, Alexanian R, Thomas SK, Orlowski RZ, Weber DM.

Am J Hematol. 2019 Dec;94(12):E319-E322. doi: 10.1002/ajh.25633. Epub 2019 Oct 4. No abstract available.

PMID:
31489991
4.

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Olsem J, Crumpton B, Morphey A, Berkova Z, Feng L, Orlowski RZ.

Haematologica. 2019 Aug 14. pii: haematol.2019.225375. doi: 10.3324/haematol.2019.225375. [Epub ahead of print]

5.

Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.

Manasanch EE, Shah JJ, Lee HC, Weber DM, Thomas SK, Amini B, Feng L, Berkova Z, Hildebrandt M, Orlowski RZ.

Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.

PMID:
30501870
6.

Considerations for Unblinding in Biopharmaceutical Industry Sponsored Trials.

Shah JJ, Bond J.

Am J Bioeth. 2018 Oct;18(10):68-70. doi: 10.1080/15265161.2018.1513588. No abstract available.

PMID:
30339068
7.

Design of complex bone internal structure using topology optimization with perimeter control.

Park J, Sutradhar A, Shah JJ, Paulino GH.

Comput Biol Med. 2018 Mar 1;94:74-84. doi: 10.1016/j.compbiomed.2018.01.001. Epub 2018 Jan 13.

PMID:
29408000
8.

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function.

Li Y, Wang X, O'Mara E, Dimopoulos MA, Sonneveld P, Weisel KC, Matous J, Siegel DS, Shah JJ, Kueenburg E, Sternas L, Cavanaugh C, Zaki M, Palmisano M, Zhou S.

Clin Pharmacol. 2017 Nov 8;9:133-145. doi: 10.2147/CPAA.S144606. eCollection 2017.

9.

Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma.

Morgan KM, Fischer BS, Lee FY, Shah JJ, Bertino JR, Rosenfeld J, Singh A, Khiabanian H, Pine SR.

Mol Cancer Ther. 2017 Dec;16(12):2759-2769. doi: 10.1158/1535-7163.MCT-17-0439. Epub 2017 Oct 4.

10.

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes.

Shah JJ, Abonour R, Gasparetto C, Hardin JW, Toomey K, Narang M, Srinivasan S, Kitali A, Zafar F, Flick ED, Rifkin RM.

Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):575-583.e2. doi: 10.1016/j.clml.2017.06.013. Epub 2017 Jun 17.

PMID:
28886839
11.

A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma.

Shah JJ, Kaufman JL, Zonder JA, Cohen AD, Bensinger WI, Hilder BW, Rush SA, Walker DH, Tunquist BJ, Litwiler KS, Ptaszynski M, Orlowski RZ, Lonial S.

Cancer. 2017 Dec 1;123(23):4617-4630. doi: 10.1002/cncr.30892. Epub 2017 Aug 17.

12.

Association of Environmental Factors, Prevalence of Asthma and Respiratory Morbidity in Mumbai: Need of a Public Health Policy.

Athavale A, Iyer H, Punwani AD, Shah JJ, Natraj G, Nair JP, Kumar R, Menon LR, Iyer AN, Raiya SJ.

J Assoc Physicians India. 2017 Jun;65(6):48-54.

PMID:
28782314
13.

A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center.

Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH.

Leuk Lymphoma. 2018 Feb;59(2):515-518. doi: 10.1080/10428194.2017.1344906. Epub 2017 Jul 3. No abstract available.

PMID:
28673185
14.

Recognition of early mortality in multiple myeloma by a prediction matrix.

Terebelo H, Srinivasan S, Narang M, Abonour R, Gasparetto C, Toomey K, Hardin JW, Larkins G, Kitali A, Rifkin RM, Shah JJ.

Am J Hematol. 2017 Sep;92(9):915-923. doi: 10.1002/ajh.24796. Epub 2017 Jul 19.

15.

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.

Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ.

Ann Hematol. 2017 Jun;96(6):977-985. doi: 10.1007/s00277-017-2980-3. Epub 2017 Mar 23.

16.

Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma: a single-institution experience.

Carballo-Zarate AA, Medeiros LJ, Fang L, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Hao S, Shen Q, Orlowski RZ, Lin P, Lu X.

Mod Pathol. 2017 Jun;30(6):843-853. doi: 10.1038/modpathol.2017.3. Epub 2017 Mar 10.

17.

Return to the Primary Acute Care Service Among Patients With Multiple Myeloma on an Acute Inpatient Rehabilitation Unit.

Fu JB, Lee J, Shin BC, Silver JK, Smith DW, Shah JJ, Bruera E.

PM R. 2017 Jun;9(6):571-578. doi: 10.1016/j.pmrj.2016.12.007. Epub 2017 Jan 8.

PMID:
28082181
18.

Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.

Bock F, Lu G, Srour SA, Gaballa S, Lin HY, Baladandayuthapani V, Honhar M, Stich M, Shah ND, Bashir Q, Patel K, Popat U, Hosing C, Korbling M, Delgado R, Rondon G, Shah JJ, Thomas SK, Manasanch EE, Isermann B, Orlowski RZ, Champlin RE, Qazilbash MH.

Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.

19.

Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma.

Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q.

Cancer. 2016 Dec 15;122(24):3831-3837. doi: 10.1002/cncr.30366. Epub 2016 Sep 28.

20.

SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage.

Hong X, Liu W, Song R, Shah JJ, Feng X, Tsang CK, Morgan KM, Bunting SF, Inuzuka H, Zheng XF, Shen Z, Sabaawy HE, Liu L, Pine SR.

Nucleic Acids Res. 2016 Oct 14;44(18):8855-8869. Epub 2016 Aug 26.

21.

Thymidine phosphorylase exerts complex effects on bone resorption and formation in myeloma.

Liu H, Liu Z, Du J, He J, Lin P, Amini B, Starbuck MW, Novane N, Shah JJ, Davis RE, Hou J, Gagel RF, Yang J.

Sci Transl Med. 2016 Aug 24;8(353):353ra113. doi: 10.1126/scitranslmed.aad8949.

22.

Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant.

Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH.

Am J Hematol. 2016 Oct;91(10):E442-7. doi: 10.1002/ajh.24487. Epub 2016 Sep 3.

23.

Lenalidomide, Thalidomide, and Pomalidomide Reactivate the Epstein-Barr Virus Lytic Cycle through Phosphoinositide 3-Kinase Signaling and Ikaros Expression.

Jones RJ, Iempridee T, Wang X, Lee HC, Mertz JE, Kenney SC, Lin HC, Baladandayuthapani V, Dawson CW, Shah JJ, Weber DM, Orlowski RZ.

Clin Cancer Res. 2016 Oct 1;22(19):4901-4912. Epub 2016 Jun 13.

24.

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ.

Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28.

25.

Practical Approaches to the Management of Dual Refractory Multiple Myeloma.

Lee HC, Mark TM, Shah JJ.

Curr Hematol Malig Rep. 2016 Apr;11(2):148-55. doi: 10.1007/s11899-016-0312-7. Review.

PMID:
26898556
26.

Does the Homograft for RVOT Reconstruction in Ross: Patients Fare Better than for Non-Ross Patients? A Single-Center Experience.

Ruzmetov M, Geiss DM, Shah JJ, Fortuna RS, Welke KF.

J Heart Valve Dis. 2015 Jul;24(4):478-83.

PMID:
26897820
27.

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial.

Shah JJ, Feng L, Thomas SK, Berkova Z, Weber DM, Wang M, Qazilbash MH, Champlin RE, Mendoza TR, Cleeland C, Orlowski RZ.

Blood Cancer J. 2016 Feb 12;6:e396. doi: 10.1038/bcj.2016.4.

28.

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.

Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B.

Clin Lymphoma Myeloma Leuk. 2016 Mar;16(3):122-8. doi: 10.1016/j.clml.2015.12.008. Epub 2015 Dec 22.

PMID:
26795083
29.

Outcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.

Badar T, Cornelison AM, Shah ND, Bashir Q, Parmar S, Patel K, Hosing C, Popat U, Weber DM, Thomas SK, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Eur J Haematol. 2016 Oct;97(4):342-7. doi: 10.1111/ejh.12736. Epub 2016 Feb 15.

PMID:
26773409
30.

Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.

Rifkin RM, Abonour R, Shah JJ, Mehta J, Narang M, Terebelo H, Gasparetto C, Toomey K, Hardin JW, Lu JJ, Kenvin L, Srinivasan S, Knight R, Nagarwala Y, Durie BG.

Leuk Lymphoma. 2016 Sep;57(9):2228-31. doi: 10.3109/10428194.2015.1132419. Epub 2016 Jan 13. No abstract available.

PMID:
26766599
31.

Outcome of Patients With Nonsecretory Multiple Myeloma After Autologous Hematopoietic Stem Cell Transplantation.

Jacobs RW, Saliba RM, Sasaki K, Farhan S, Armas A, Shah ND, Bashir Q, Qureshi S, Rondon G, Hosing C, Popat U, Parmar S, Shah JJ, Wang M, Weber DM, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):36-42. doi: 10.1016/j.clml.2015.11.005. Epub 2015 Dec 1.

PMID:
26702475
32.

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.

Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial S.

Clin Cancer Res. 2016 Jan 1;22(1):34-43. doi: 10.1158/1078-0432.CCR-15-1237. Epub 2015 Nov 11.

33.

Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.

Cao X, Medeiros LJ, Xia Y, Wang X, Thomas SK, Loghavi S, Li X, Shah JJ, Gustafson SA, Weber DM, Miranda RN, Xu-Monette ZY, Orlowski RZ, Young KH.

Leuk Lymphoma. 2016 May;57(5):1104-13. doi: 10.3109/10428194.2015.1096357. Epub 2015 Dec 23.

PMID:
26421453
34.

Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.

Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Gomes CL, Pascucci N, Smith DD, Orlowski RZ, Durie BG.

Blood. 2015 Nov 12;126(20):2284-90. doi: 10.1182/blood-2015-05-643320. Epub 2015 Sep 17.

35.

Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.

Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):687-93. doi: 10.1016/j.clml.2015.07.641. Epub 2015 Aug 5.

36.

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.

Usmani SZ, Sexton R, Ailawadhi S, Shah JJ, Valent J, Rosenzweig M, Lipe B, Zonder JA, Fredette S, Durie B, Hoering A, Bartlett B, Orlowski RZ.

Blood Cancer J. 2015 Aug 7;5:e334. doi: 10.1038/bcj.2015.62. No abstract available.

37.

Design, synthesis and evaluation of benzotriazole derivatives as novel antifungal agents.

Shah JJ, Khedkar V, Coutinho EC, Mohanraj K.

Bioorg Med Chem Lett. 2015 Sep 1;25(17):3730-7. doi: 10.1016/j.bmcl.2015.06.025. Epub 2015 Jun 14.

PMID:
26117563
38.

The Association Between Aortic Valve Leaflet Morphology and Patterns of Aortic Dilation in Patients With Bicuspid Aortic Valves.

Ruzmetov M, Shah JJ, Fortuna RS, Welke KF.

Ann Thorac Surg. 2015 Jun;99(6):2101-7; discussion 2107-8. doi: 10.1016/j.athoracsur.2015.02.036. Epub 2015 Apr 25.

PMID:
25921253
39.

Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.

Afrough A, Saliba RM, Hamdi A, El Fakih R, Varma A, Dinh YT, Rondon G, Cornelison AM, Shah ND, Bashir Q, Shah JJ, Hosing C, Popat U, Orlowski RZ, Champlin RE, Parmar S, Qazilbash MH.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1413-7. doi: 10.1016/j.bbmt.2015.03.025. Epub 2015 Apr 2.

40.

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia.

Kuiatse I, Baladandayuthapani V, Lin HY, Thomas SK, Bjorklund CC, Weber DM, Wang M, Shah JJ, Zhang XD, Jones RJ, Ansell SM, Yang G, Treon SP, Orlowski RZ.

Clin Cancer Res. 2015 Jun 1;21(11):2538-45. doi: 10.1158/1078-0432.CCR-14-1462. Epub 2015 Mar 6.

41.

High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.

Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S.

Bone Marrow Transplant. 2015 May;50(5):668-72. doi: 10.1038/bmt.2015.21. Epub 2015 Mar 2.

PMID:
25730192
42.

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH.

Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27. No abstract available.

43.

Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics.

Rifkin RM, Abonour R, Terebelo H, Shah JJ, Gasparetto C, Hardin J, Srinivasan S, Ricafort R, Nagarwala Y, Durie BG.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):368-76. doi: 10.1016/j.clml.2014.12.002. Epub 2014 Dec 11.

PMID:
25617035
45.

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease.

Samaniego F, Berkova Z, Romaguera JE, Fowler N, Fanale MA, Pro B, Shah JJ, McLaughlin P, Sehgal L, Selvaraj V, Braun FK, Mathur R, Feng L, Neelapu SS, Kwak LW.

Br J Haematol. 2014 Oct;167(2):207-13. doi: 10.1111/bjh.13021. Epub 2014 Jul 8.

PMID:
25040450
46.

Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.

Parmar S, Kongtim P, Champlin R, Dinh Y, Elgharably Y, Wang M, Bashir Q, Shah JJ, Shah N, Popat U, Giralt SA, Orlowski RZ, Qazilbash MH.

Bone Marrow Transplant. 2014 Aug;49(8):1036-41. doi: 10.1038/bmt.2014.115. Epub 2014 Jun 2.

PMID:
24887378
47.
48.

Tuberculin Skin Tests versus Interferon-Gamma Release Assays in Tuberculosis Screening among Immigrant Visa Applicants.

Chuke SO, Yen NT, Laserson KF, Phuoc NH, Trinh NA, Nhung DT, Mai VT, Qui AD, Hai HH, Loan le TH, Jones WG, Whitworth WC, Shah JJ, Painter JA, Mazurek GH, Maloney SA.

Tuberc Res Treat. 2014;2014:217969. doi: 10.1155/2014/217969. Epub 2014 Mar 6.

49.

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.

Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8. doi: 10.1016/j.bbmt.2013.07.008. Epub 2013 Jul 17.

50.

Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications.

Bjorklund CC, Baladandayuthapani V, Lin HY, Jones RJ, Kuiatse I, Wang H, Yang J, Shah JJ, Thomas SK, Wang M, Weber DM, Orlowski RZ.

Leukemia. 2014 Feb;28(2):373-83. doi: 10.1038/leu.2013.174. Epub 2013 Jun 13.

Supplemental Content

Support Center